2023

  1. ICD-10-CM Codes
    2. ›
  2. C00-D49
    3. ›
  3. C81-C96
    4. ›
  4. C96-
    5. ›
  5. 2023 ICD-10-CM Diagnosis Code C96.2

2023 ICD-10-CM Diagnosis Code C96.2

Malignant mast cell neoplasm

    2016 2017 2018 - Converted to Parent Code 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
  • C96.2 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2023 edition of ICD-10-CM C96.2 became effective on October 1, 2022.
  • This is the American ICD-10-CM version of C96.2 - other international versions of ICD-10 C96.2 may differ.
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C96.2. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • indolent mastocytosis (
    ICD-10-CM Diagnosis Code D47.02

    Systemic mastocytosis

      2018 - New Code 2019 2020 2021 2022 2023 Billable/Specific Code
    Applicable To
    • Indolent systemic mastocytosis
    • Isolated bone marrow mastocytosis
    • Smoldering systemic mastocytosis
    • Systemic mastocytosis, with an associated hematological non-mast cell lineage disease (SM-AHNMD)
    Code Also
    • , if applicable, any associated hematological non-mast cell lineage disease, such as:
    • acute myeloid leukemia (C92.6-, C92.A-)
    • chronic myelomonocytic leukemia (C93.1-)
    • essential thrombocytosis (D47.3)
    • hypereosinophilic syndrome (D72.1)
    • myelodysplastic syndrome (D46.9)
    • myeloproliferative syndrome (D47.1)
    • non-Hodgkin lymphoma (C82-C85)
    • plasma cell myeloma (C90.0-)
    • polycythemia vera (D45)
    Type 1 Excludes
    • aggressive systemic mastocytosis (C96.21)
    • mast cell leukemia (C94.3-)
    D47.02
    )
  • mast cell leukemia (
    ICD-10-CM Diagnosis Code C94.30

    Mast cell leukemia not having achieved remission

      2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
    Applicable To
    • Mast cell leukemia with failed remission
    • Mast cell leukemia NOS
    C94.30
    )
  • mastocytosis (congenital) (cutaneous) (
    ICD-10-CM Diagnosis Code Q82.2

    Congenital cutaneous mastocytosis

      2016 2017 2018 - Revised Code 2019 2020 2021 2022 2023 Billable/Specific Code POA Exempt
    Applicable To
    • Congenital diffuse cutaneous mastocytosis
    • Congenital maculopapular cutaneous mastocytosis
    • Congenital urticaria pigmentosa
    Type 1 Excludes
    • cutaneous mastocytosis NOS (D47.01)
    • diffuse cutaneous mastocytosis (with onset after newborn period) (D47.01)
    • malignant mastocytosis (C96.2-)
    • systemic mastocytosis (D47.02)
    • urticaria pigmentosa (non-congenital) (with onset after newborn period) (D47.01)
    Q82.2
    )
The following code(s) above C96.2 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C96.2:
  • C00-D49
    2023 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C81-C96
    2023 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
  • C96
    ICD-10-CM Diagnosis Code C96

    Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue

      2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues (Z85.79)
    Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
Approximate Synonyms
  • Lymphoma intra abdominal, mast cell
  • Lymphoma intrapelvic, mast cell
  • Lymphoma intrathoracic, mast cell
  • Lymphoma multiple sites, mast cell
  • Lymphoma spleen, mast cell
  • Lymphoma, mast cell
  • Malignant mast cell tumor (clinical)
  • Malignant mast cell tumor of intra-abdominal lymph nodes
  • Malignant mast cell tumor of intrapelvic lymph nodes
  • Malignant mast cell tumor of intrathoracic lymph nodes
  • Malignant mast cell tumor of lymph nodes of axilla
  • Malignant mast cell tumor of lymph nodes of head
  • Malignant mast cell tumor of lymph nodes of inguinal region
  • Malignant mast cell tumor of lymph nodes of lower limb
  • Malignant mast cell tumor of lymph nodes of multiple sites
  • Malignant mast cell tumor of lymph nodes of neck
  • Malignant mast cell tumor of lymph nodes of upper limb
  • Malignant mast cell tumor, arm ln
  • Malignant mast cell tumor, axillary ln
  • Malignant mast cell tumor, head ln
  • Malignant mast cell tumor, inguinal ln
  • Malignant mast cell tumor, leg ln
  • Malignant mast cell tumor, neck ln
  • Mast cell malignancy of spleen
  • Mastocytosis, systemic
  • Systemic mast cell disease
Clinical Information
  • A form of systemic mastocytosis in which patients have impaired organ functions due to multifocal infiltrates of pathological mast cells in bone marrow, liver, spleen, gastrointestinal tract, or skeletal system. The cytomorphology shows a low to high grade.
  • A rare entity characterized by localized but destructive growth of a tumor consisting of highly atypical, immature mast cells.(who, 2001)
  • A unifocal malignant tumor that consists of atypical pathological mast cells without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.
  • An aggressive and progressive mast cell neoplasm characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells.
  • An aggressive and progressive mast cell neoplasm characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinical symptoms include hepatomegaly, splenomegaly, portal hypertension, malabsorption syndrome, and pathologic fractures.
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): Deleted code
  • 2018 (effective 10/1/2017): New code
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
Code annotations containing back-references to C96.2:
  • Type 1 Excludes: D47.0
    , D89.4
    , Q82.2
    ICD-10-CM Diagnosis Code D47.0

    Mast cell neoplasms of uncertain behavior

      2016 2017 2018 - Converted to Parent Code 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • congenital cutaneous mastocytosis (Q82.2)
    • histiocytic neoplasms of uncertain behavior (D47.Z9)
    • malignant mast cell neoplasm (C96.2-)
    ICD-10-CM Diagnosis Code D89.4

    Mast cell activation syndrome and related disorders

      2017 - New Code 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • aggressive systemic mastocytosis (C96.21)
    • congenital cutaneous mastocytosis (Q82.2)
    • (non-congenital) cutaneous mastocytosis (D47.01)
    • (indolent) systemic mastocytosis (D47.02)
    • malignant mast cell neoplasm (C96.2-)
    • malignant mastocytoma (C96.29)
    • mast cell leukemia (C94.3-)
    • mast cell sarcoma (C96.22)
    • mastocytoma NOS (D47.09)
    • other mast cell neoplasms of uncertain behavior (D47.09)
    • systemic mastocytosis associated with a clonal hematologic non-mast cell lineage disease (SM-AHNMD) (D47.02)
    ICD-10-CM Diagnosis Code Q82.2

    Congenital cutaneous mastocytosis

      2016 2017 2018 - Revised Code 2019 2020 2021 2022 2023 Billable/Specific Code POA Exempt
    Applicable To
    • Congenital diffuse cutaneous mastocytosis
    • Congenital maculopapular cutaneous mastocytosis
    • Congenital urticaria pigmentosa
    Type 1 Excludes
    • cutaneous mastocytosis NOS (D47.01)
    • diffuse cutaneous mastocytosis (with onset after newborn period) (D47.01)
    • malignant mastocytosis (C96.2-)
    • systemic mastocytosis (D47.02)
    • urticaria pigmentosa (non-congenital) (with onset after newborn period) (D47.01)
ICD-10-CM Codes Adjacent To C96.2
C95.1 Chronic leukemia of unspecified cell type
C95.10 …… not having achieved remission
C95.11 …… in remission
C95.12 …… in relapse
C95.9 Leukemia, unspecified
C95.90 …… not having achieved remission
C95.91 …… in remission
C95.92 …… in relapse
C96 Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.0 Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.2 Malignant mast cell neoplasm
C96.20 …… unspecified
C96.21 Aggressive systemic mastocytosis
C96.22 Mast cell sarcoma
C96.29 Other malignant mast cell neoplasm
C96.4 Sarcoma of dendritic cells (accessory cells)
C96.5 Multifocal and unisystemic Langerhans-cell histiocytosis
C96.6 Unifocal Langerhans-cell histiocytosis
C96.A Histiocytic sarcoma
C96.Z Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.9 Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Advertise with Us | License ICD10 Data

Copyright © | ICD10data.com